You just read:

Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA

News provided by

Can-Fite BioPharma Ltd.

Nov 01, 2016, 07:00 ET